Macrogenics Inc (MGNX) Beta Value: Understanding the Market Risk

The 36-month beta value for MGNX is also noteworthy at 2.07. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 5 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”

The public float for MGNX is 58.01M, and at present, short sellers hold a 9.25% of that float. The average trading volume of MGNX on November 06, 2024 was 637.59K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

MGNX) stock’s latest price update

Macrogenics Inc (NASDAQ: MGNX) has seen a rise in its stock price by 15.65 in relation to its previous close of 3.77. However, the company has experienced a 28.24% gain in its stock price over the last five trading sessions. zacks.com reported 2024-11-05 that The headline numbers for MacroGenics (MGNX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

MGNX’s Market Performance

Macrogenics Inc (MGNX) has seen a 28.24% rise in stock performance for the week, with a 20.44% gain in the past month and a 26.38% surge in the past quarter. The volatility ratio for the week is 8.80%, and the volatility levels for the past 30 days are at 6.93% for MGNX. The simple moving average for the past 20 days is 13.69% for MGNX’s stock, with a -49.47% simple moving average for the past 200 days.

Analysts’ Opinion of MGNX

B. Riley Securities gave a rating of “Neutral” to MGNX, setting the target price at $5 in the report published on July 31st of the current year.

MGNX Trading at 22.03% from the 50-Day Moving Average

After a stumble in the market that brought MGNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.07% of loss for the given period.

Volatility was left at 6.93%, however, over the last 30 days, the volatility rate increased by 8.80%, as shares surge +18.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.53% upper at present.

During the last 5 trading sessions, MGNX rose by +27.65%, which changed the moving average for the period of 200-days by -63.86% in comparison to the 20-day moving average, which settled at $3.83. In addition, Macrogenics Inc saw -54.68% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at MGNX starting from Peters Jeffrey Stuart, who sale 51,395 shares at the price of $15.55 back on Apr 04 ’24. After this action, Peters Jeffrey Stuart now owns 0 shares of Macrogenics Inc, valued at $799,148 using the latest closing price.

Peters Jeffrey Stuart, the Senior VP and General Counsel of Macrogenics Inc, sale 19,625 shares at $21.50 during a trade that took place back on Mar 06 ’24, which means that Peters Jeffrey Stuart is holding 8,895 shares at $421,938 based on the most recent closing price.

Stock Fundamentals for MGNX

Current profitability levels for the company are sitting at:

  • -0.76 for the present operating margin
  • 0.92 for the gross margin

The net margin for Macrogenics Inc stands at -0.69. The total capital return value is set at -0.52. Equity return is now at value -62.17, with -32.30 for asset returns.

Based on Macrogenics Inc (MGNX), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -1.7. The debt to equity ratio resting at 0.28. The interest coverage ratio of the stock is 62.23.

Currently, EBITDA for the company is -158.6 million with net debt to EBITDA at 1.43. When we switch over and look at the enterprise to sales, we see a ratio of 0.86. The receivables turnover for the company is 16.15for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.75.

Conclusion

In summary, Macrogenics Inc (MGNX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts